A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)

Summary

The purpose of this study was to evaluate the efficacy of mirabegron in children (5 to \< 12 years of age) with OAB. This study will also evaluated the safety and tolerability of mirabegron in pediatric participants with OAB and evaluated the pharmacokinetics after multiple dose administration of mirabegron in pediatric participants with OAB.

Timeline

Start

2021-03-15

Primary completion

2023-07-07

Completion

2023-07-24

Drugs

Indications